A Queens Counsel and a junior barrister at the Victorian Bar are taking DLA Piper to court, accusing the law firm of failing to pay more than $370,000 in fees.
The Australian Securities & Investments Commission has largely prevailed on appeal to the High Court in its case against former directors of collapsed retirement village owner Prime Trust, including former federal health minister Michael Wooldridge.
Pacific National would not misuse its market power after taking control of an important rail terminal in Brisbane because that would be “irrational”, the Federal Court heard Monday at the start of a two-week trial in the competition watchdog’s case alleging the rail giant colluded with competitor Aurizon to become the dominant operator of key freight corridors.
Drug maker Neurim Pharmaceuticals is battling to amend its Australian patent for the blockbuster sleeping pill Circadin over opposition from two generic pharmaceutical companies, which have accused Neurim of attempting to gain an unfair advantage by delaying the amendment bid until now.
Wyeth must pay a group of generic drug companies for the harm they suffered after the drug maker won interlocutory injunctions blocking their plans to market an extended release generic version of anti-depressant Effexor, in a ruling likely to have a chilling effect on interlocutory injunction grants in pharmaceutical patent cases.
Domino’s Pizza and Precision Tracking have reached a settlement on the eve of trial in a hard-fought battle by the US pizza giant to invalidate two of the Australian tech startup’s patents covering a GPS system that helps customers locate delivery drivers in real-time.
The Commonwealth of Australia has resolved its claims against pharmaceutical giant Wyeth over the price it paid to list Effexor on the PBS, months after a high stakes trial wrapped up.
Aurizon has won a request to view documents from Qube Holdings in the ACCC’s case alleging it reached an anti-competitive agreement with Pacific National for the sale of its intermodal freight business, as it pushes back against the competition regulator’s claim that there were other buyers vying for the business.
An investor suing property investment group Aviation 3030 can’t avoid payment of half a million dollars in security for litigation costs because of a parallel enforcement action by the corporate regulator, a judge has ruled.
The Australian Patent Office has thrown out Fisher & Paykel Healthcare’s opposition to a patent for a gas supply apparatus used to treat respiratory conditions owned by California-based medical equipment manufacturer, ResMed.